Gleason pattern 4 and active surveillance in patients with grade group 2 prostate cancer.

IF 5.8 2区医学 Q1 ONCOLOGY

Prostate Cancer and Prostatic Diseases Pub Date : 2025-04-29 DOI:10.1038/s41391-025-00977-6

Alessandro Uleri, Michael Baboudjian, Riccardo Leni, Marco Oderda, Arthur Peyrottes, Claudia Kesch, Mulham Al-Nader, Charles Dariane, Helene Baud, Jonathan Olivier, Anna Redondo Rios, Francesco Sanguedolce, Vincent Benard, Olivier Windisch, Massimo Valerio, Giorgio Gandaglia, Guillaume Ploussard

{"title":"Gleason pattern 4 and active surveillance in patients with grade group 2 prostate cancer.","authors":"Alessandro Uleri, Michael Baboudjian, Riccardo Leni, Marco Oderda, Arthur Peyrottes, Claudia Kesch, Mulham Al-Nader, Charles Dariane, Helene Baud, Jonathan Olivier, Anna Redondo Rios, Francesco Sanguedolce, Vincent Benard, Olivier Windisch, Massimo Valerio, Giorgio Gandaglia, Guillaume Ploussard","doi":"10.1038/s41391-025-00977-6","DOIUrl":null,"url":null,"abstract":"Background: To report active surveillance (AS) outcomes in patients with Grade Group (GG) 2 prostate cancer (PCa) according to the baseline amount of pattern 4 on image-guided biopsy.Methods: Our database includes GG2 PCa patients managed with AS in ten European centers.Results: In total, 104 patients were included (median pattern 4: 10%, ranges 5-40). The percentage of pattern 4 was not statistically correlated with upgrading (Spearman, r = 0.073, p = 0.5) or downgrading on confirmatory biopsy (r = -0.049, p = 0.6). The median follow-up was 33 months. In multivariable Cox regression analysis, percentage of pattern 4 was not associated with GG3 upgrading (p = 0.6) or definitive treatment (p = 0.4).Conclusions: Patients with GG2 PCa should not be excluded from AS solely because of grade 4 > 10% when other parameters are otherwise favorable.","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.8000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate Cancer and Prostatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41391-025-00977-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To report active surveillance (AS) outcomes in patients with Grade Group (GG) 2 prostate cancer (PCa) according to the baseline amount of pattern 4 on image-guided biopsy.

Methods: Our database includes GG2 PCa patients managed with AS in ten European centers.

Results: In total, 104 patients were included (median pattern 4: 10%, ranges 5-40). The percentage of pattern 4 was not statistically correlated with upgrading (Spearman, r = 0.073, p = 0.5) or downgrading on confirmatory biopsy (r = -0.049, p = 0.6). The median follow-up was 33 months. In multivariable Cox regression analysis, percentage of pattern 4 was not associated with GG3 upgrading (p = 0.6) or definitive treatment (p = 0.4).

Conclusions: Patients with GG2 PCa should not be excluded from AS solely because of grade 4 > 10% when other parameters are otherwise favorable.

查看原文本刊更多论文

Gleason模式4和主动监测2级前列腺癌患者。

背景：根据图像引导活检中模式4的基线量，报告2级组（GG）前列腺癌（PCa）患者的主动监测（AS）结果。方法：我们的数据库包括10个欧洲中心的GG2 PCa患者。结果：共纳入104例患者（中位模式4:10%，范围5- 40%）。模式4的百分比与确诊活检的升级（Spearman, r = 0.073, p = 0.5）或降级（r = -0.049, p = 0.6）无统计学相关性。中位随访时间为33个月。在多变量Cox回归分析中，模式4的百分比与GG3升级（p = 0.6）或最终治疗（p = 0.4）无关。结论：当其他参数有利时，GG2型PCa患者不应仅仅因为4级bbb10 %而被排除在AS之外。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostate Cancer and Prostatic Diseases 医学-泌尿学与肾脏学

CiteScore

10.00

自引率

6.20%

发文量

142

审稿时长

6-12 weeks

期刊介绍： Prostate Cancer and Prostatic Diseases covers all aspects of prostatic diseases, in particular prostate cancer, the subject of intensive basic and clinical research world-wide. The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery and medical management. Prostate Cancer and Prostatic Diseases is of interest to surgeons, oncologists and clinicians treating patients and to those involved in research into diseases of the prostate. The journal covers the three main areas - prostate cancer, male LUTS and prostatitis. Prostate Cancer and Prostatic Diseases publishes original research articles, reviews, topical comment and critical appraisals of scientific meetings and the latest books. The journal also contains a calendar of forthcoming scientific meetings. The Editors and a distinguished Editorial Board ensure that submitted articles receive fast and efficient attention and are refereed to the highest possible scientific standard. A fast track system is available for topical articles of particular significance.